Clinical trial
The Determination of the First Dose and the Optimal Time of Administration of Insulin Glargine Combined With Oral Antidiabetic Drug in Poorly Controlled Type II Diabetic Patients
NCT00349986 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Determination of the First Dose and the Optimal Time of Administration of Insulin Glargine Combined With Oral Antidiabetic Drug in Poorly Controlled Type II Diabetic Patients
- Lead sponsor
- Sanofi
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- September 30, 2006
- Completion date
- Not reported
- Enrollment
- 4 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.